News

Renal Cell Carcinoma Pipeline Appears Robust With 30+ Companies Actively Working in the Therapeutics Segment | DelveInsight
DelveInsight’s Renal Cell Carcinoma Pipeline report depicts a robust space with 30+ active players working to develop 30+ ...
Sensei Biotherapeutics Reports First Quarter 2025 Financial Results and Updates on Clinical Progress
Favorable clinical data in PD-(L)1 resistant patients - - Dose expansion enrollment complete with full data expected by ...
The Manila Times4d
Immuneering Reports First Quarter 2025 Financial Results and Provides Business Updates
CAMBRIDGE, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize more effective and better tolerated ...
manilatimes9d
Lewis Hamilton Foundation Mission 44 and HP Inc. Join Forces to Drive STEM Skills and Future of Work Readiness for Young People
MIAMI, May 01, 2025 (GLOBE NEWSWIRE) -- Today at the F1 Miami Grand Prix circuit, Sir Lewis Hamilton's global foundation ...
Regeneron Pharmaceuticals, Inc.: Lynozyfic (linvoseltamab) Approved in the European Union for the Treatment of Relapsed/Refractory Multiple Myeloma
Approval of Lynozyfic is based on data showing deep and durable responses in relapsed/refractory multiple myeloma Lynozyfic will provide a new option with convenient dosing and administration to patie ...
TMCnet15d
BioNTech to Present Clinical and Preclinical Data Across mRNA and Next-Generation Immuno-Oncology Priority Programs at AACR 2025
Highlights of BioNTech’s oncology programs to be presented at AACR 2025: ...
PipelineReview.com15d
Bioxodes announces positive Phase 2a interim data for BIOX-101 in intracerebral hemorrhagic stroke patients
GOSSELIES, Belgium I April 24, 2025 I Bioxodes SA, a clinical stage biopharmaceutical company developing novel therapies for the prevention and treatment of thrombotic and inflammatory diseases, today ...
Targeted Oncology18d
ICIs Effective Regardless of Patients' Age, But Key Immune Phenotype Differences May Enable Tailored Regimens
Patients with pathologically confirmed solid tumors were treated with ICIs consisting of anti-PD-1/PD-L1 blockade (nivolumab [Opdivo], pembrolizumab [Keytruda], atezolizumab [Tecentriq], cemiplimab ...
BioSpace19d
Dupixent® (dupilumab) Approved in the U.S. as the First New Targeted Therapy in Over a Decade for Chronic Spontaneous Urticaria (CSU)
TARRYTOWN, N.Y. and PARIS, April 18, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved ...
Cancer Research19d
Identification of Early-Stage Breast Cancer with a Minimal Risk of Recurrence by the Breast Cancer Index
1Department of Surgery, Leiden University Medical Center, Leiden, the Netherlands. *Corresponding Author: Gerrit Jan Liefers, Department of Surgery, Leiden University Medical Center, Albinusdreef 2, ...